Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA
US biotech SQZ Biotechnologies has expanded a collaboration with Roche to develop cancer therapies based on antigen presenting cells, which may be able to target solid tumours and which are
Gilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors that could lead to cell therapies capable of targeting solid tumours.